BioCentury
ARTICLE | Clinical News

Prolia Denosumab: Phase III data

August 1, 2011 7:00 AM UTC

In its 2Q11 earnings, Amgen said data from the double-blind Phase III ADAMO trial in 242 men with osteoporosis showed that 60 mg Prolia denosumab met the primary endpoint of a significantly greater percent change in lumbar spine BMD at 12 months vs. placebo. Prolia also met all secondary endpoints. The company said safety data were consistent with what has been previously reported in other populations. Details were not disclosed. ...